Abstract
Intravenous immune globulin (IVIG) is made after processing plasma from healthy donors. It is composed mainly of pooled immunoglobulin and has clinical evidence-based applications in adult and pediatric populations. Recently, several clinical applications have been proposed for managing conditions in the neonatal population, such as hemolytic disease of the newborn, treatment, and prophylaxis for sepsis in high-risk neonates, enterovirus parvovirus and COVID-19 related neonatal infections, fetal and neonatal immune-induced thrombocytopenia, neonatal hemochromatosis, neonatal Kawasaki disease, and some types of immunodeficiency. The dosing, mechanism of action, effectiveness, side effects, and adverse reactions of IVIG have been relatively well studied in adults but are not well described in the neonatal population. This review aims to provide the most recent evidence and consensus guidelines about the use of IVIG in the fetus and neonate.
Highlights
Immunoglobulin therapy is defined as the use of a combination of antibodies obtained from healthy human donors to treat different conditions [1,2]
The use these clinical applications have extended to include children, neonates, and fetuses of immunoglobulin isolated from the human serum in non-infectious conditions was[8,9]
The use of immunoglobulin isolated from the human serum in non-infectious conditions was Recently, tremendous effort has been placed on the role of intravenous immunoglobulin (IVIG) therapy to treat complications related first reported in International collaborations were organized to investigate the use of to Coronavirus-19 viral infection in adults as well as the pediatric and neonatal population
Summary
Immunoglobulin therapy is defined as the use of a combination of antibodies obtained from healthy human donors to treat different conditions [1,2]. Several of mid-20th century, IVIG usesand revolved aroundhave the management of infectious diseases The use these clinical applications have extended to include children, neonates, and fetuses of immunoglobulin isolated from the human serum in non-infectious conditions was[8,9]. Expanded efforts suggested usingofthe intravenous in the management of or specific cytotoxicity, regulating apoptosis, modulation of antigen-presenting cells) were the driving factors conditions in the non-adult population [18,19]. The use of immunoglobulin isolated from the human serum in non-infectious conditions was Recently, tremendous effort has been placed on the role of IVIG therapy to treat complications related first reported in [16]. Tremendous effort has been placed on the role of IVIG therapy to treat complications related to Coronavirus-19 viral infection in adults as well as the pediatric and neonatal population. FNAIT: fetal and neonatal alloimmune thrombocytopenia, ITP: idiopathic thrombocytopenic purpura, COVID-19: coronavirus disease 19, CMV: cytomegalovirus, GALD: gestational autoimmune liver disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
